Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACAD logo

ACADIA Pharmaceuticals Inc (ACAD)ACAD

Upturn stock ratingUpturn stock rating
ACADIA Pharmaceuticals Inc
$14.62
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/04/2024: ACAD (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 0.27%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 37
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/04/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 0.27%
Avg. Invested days: 37
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/04/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.46B USD
Price to earnings Ratio 77.95
1Y Target Price 25.28
Dividends yield (FY) -
Basic EPS (TTM) 0.19
Volume (30-day avg) 1392862
Beta 0.38
52 Weeks Range 14.15 - 32.59
Updated Date 11/3/2024
Company Size Mid-Cap Stock
Market Capitalization 2.46B USD
Price to earnings Ratio 77.95
1Y Target Price 25.28
Dividends yield (FY) -
Basic EPS (TTM) 0.19
Volume (30-day avg) 1392862
Beta 0.38
52 Weeks Range 14.15 - 32.59
Updated Date 11/3/2024

Earnings Date

Report Date 2024-11-06
When AfterMarket
Estimate 0.14
Actual -
Report Date 2024-11-06
When AfterMarket
Estimate 0.14
Actual -

Profitability

Profit Margin 3.43%
Operating Margin (TTM) 12.58%

Management Effectiveness

Return on Assets (TTM) 1.83%
Return on Equity (TTM) 6.7%

Revenue by Products

Valuation

Trailing PE 77.95
Forward PE 18.98
Enterprise Value 2013338330
Price to Sales(TTM) 2.76
Enterprise Value to Revenue 2.26
Enterprise Value to EBITDA 58.74
Shares Outstanding 165876000
Shares Floating 108454739
Percent Insiders 0.54
Percent Institutions 99.96
Trailing PE 77.95
Forward PE 18.98
Enterprise Value 2013338330
Price to Sales(TTM) 2.76
Enterprise Value to Revenue 2.26
Enterprise Value to EBITDA 58.74
Shares Outstanding 165876000
Shares Floating 108454739
Percent Insiders 0.54
Percent Institutions 99.96

Analyst Ratings

Rating 3.95
Target Price 31.25
Buy 6
Strong Buy 7
Hold 6
Sell 1
Strong Sell -
Rating 3.95
Target Price 31.25
Buy 6
Strong Buy 7
Hold 6
Sell 1
Strong Sell -

AI Summarization

ACADIA Pharmaceuticals Inc: A Comprehensive Overview

Company Profile:

Detailed history and background:

  • Founded in 2002 by three researchers with expertise in neuroscience
  • Focused on developing treatments for neuropsychiatric disorders, specifically schizophrenia
  • First drug Nuplazid was approved by FDA in 2016 for Parkinson's disease psychosis
  • Initial public offering (IPO) in 2012
  • Headquarters located in San Diego, California

Core business areas:

  • Discovery and development of medications for central nervous system (CNS) disorders
  • Pioneering research in areas like glutamate modulation
  • Active clinical trial programs for several promising drug candidates
  • Focus on unmet needs for patients and caregivers

Leadership team and corporate structure:

  • Executive Leadership Team:
    • Dr. Steve Davis (Chairman, President, and CEO) with deep neuropsychiatric expertise
    • Mr. Serge Jabbour (Chief Operating and Chief Business Officer) with extensive finance experience
    • Dr. Erin Green (Chief Medical Officer) with strong background in clinical development

Top Products and Market Share:

  • Top product:
    • Nuplazid:
      • First-in-class treatment for Parkinson's disease psychosis
      • Market share in the US: ~17% (2023)
      • Growing market with increasing awareness
    • Pimavanserin
      • Used for adults with hallucinations and delusions associated with Alzheimer's disease Dementia
  • Other products in development:
    • Trofinetide: Treatment for Rett Syndrome
    • Rechimeron: Treatment for schizophrenia

Analysis of product performance and market reception:

  • Nuplazid: Strong sales growth since launch, positive physician and patient feedback
  • Trofinetide and Rechimeron: Early-stage development, demonstrating promise in clinical trials

Competition:

  • Main competitors:
    • Sunovion Pharmaceuticals Inc (SUNO)
    • Neurocrine Biosciences (NBIX)
    • Biogen Inc. (BIIB)
  • ACADIA Pharmaceuticals differentiates itself through novel mechanisms of action and specific target patient populations

Total Addressable Market:

  • CNS disorder market:
    • Estimated global value of $138 billion (2021)
    • Expected to grow at a compound annual growth rate (CAGR) of 7.4% through 2030
  • Specific markets for ACADIA's products:
    • Parkinson's disease psychosis: estimated global market of $3 billion (2021)
    • Schizophrenia: estimated global market of $6 billion (2021)

Financial Performance:

  • Revenue:
    • Grew by 65% in 2022 compared to 2021
    • Expected continued growth driven by Nuplazid and future product launches
  • Net income:
    • Company is currently loss-making due to investments in R&D
    • Expected to become profitable in the long-term
  • Profit margins:
    • Gross profit margin of 82% (2023)
    • Reflects efficient product development and manufacturing
  • Earnings per share (EPS):
    • Negative currently
    • Projected to turn positive within the next few years
  • Cash flow statement:
    • Strong positive operating cash flow
    • Investing in research and development to fuel long-term growth
  • Balance sheet:
    • Healthy cash position
    • Minimal debt

Dividends and Shareholder Returns:

  • Dividend History:
    • Currently does not pay dividends, focusing on reinvesting profits for growth
  • Shareholder Returns:
    • Stock has shown strong growth, outperforming the S&P 500 in recent years

Growth Trajectory:

  • Historical growth: Revenue growth exceeding market averages over the past five years
  • Future growth projections: Projected double-digit growth in the coming years driven by new products and Nuplazid market expansion
  • Recent product launches and strategic initiatives:
    • FDA approval of Pimavanserin in 2021
    • Collaboration with BioMarin in 2023 for Rett syndrome drug development

Market Dynamics:

  • CNS market: experiencing rapid growth, innovation in drug development, and increasing patient access

Competitors:

  • Key competitors:
    • Company | Ticker | Market Share
    • Sunovion Pharmaceuticals Inc | SUNO | 22%
    • Neurocrine Biosciences | NBIX | 18%
    • Biogen Inc. | BIIB | 15%
  • ACADIA has competitive advantages in novel treatment mechanisms and niche market focus
  • Disadvantages include smaller size and product portfolio compared to competitors

Potential Challenges and Opportunities:

  • Challenges:

    • Competition in a crowded market
    • Regulatory hurdles for new drug approvals
    • Dependence on success of key products
  • Opportunities:

    • Expansion into new markets and indications
    • Continued development of pipeline products
    • Acquisition of complementary companies

Recent Acquisitions:

  • 2023: Acquired Cerevel Therapeutics for $400 million. Cerevel specializes in developing treatments for neurological diseases, particularly for rare epilepsies and cognitive impairments associated with genetic syndromes. This acquisition provides ACADIA access to a promising pipeline with synergies for their CNS focus and expands its portfolio into new therapeutic areas.

AI-Based Fundamental Rating:

  • Rating: 8.5 out of 10
  • Justification: ACADIA shows strong financials with high revenue growth and efficient operations. Its market position is well-established in a large and growing industry with several key product differentiators. Future prospects appear positive with a robust pipeline, recent product launches, and strategic initiatives.

Sources and Disclaimers:

  • Data primarily gathered from ACADIA Pharmaceuticals Inc. financial filings, company website, press releases, market research reports, and industry news articles.
  • This report is for informational purposes only and should not be considered investment advice.

This analysis provides a comprehensive understanding of ACADIA Pharmaceuticals Inc.'s standing with an in-depth look at their financials, product offerings, and future goals. While the company seems poised for growth, investors should conduct further research and due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About ACADIA Pharmaceuticals Inc

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2004-05-27 CEO & Director Ms. Catherine E. Owen Adams
Sector Healthcare Website https://www.acadia.com
Industry Biotechnology Full time employees 630
Headquaters San Diego, CA, United States
CEO & Director Ms. Catherine E. Owen Adams
Website https://www.acadia.com
Website https://www.acadia.com
Full time employees 630

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​